Organon & Co. (OGN) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Organon & Co. is set to release its Q2 2025 earnings on August 5th, with analysts projecting earnings of $0.93 per share and revenue of $1.55 billion.
• The company's recent earnings report showed a year-over-year revenue decline of 6.7%, despite beating EPS expectations with $1.02 per share against the anticipated $0.89.
• Analysts have mixed sentiments on the stock, with ratings ranging from a strong buy to an equal weight, and an average price target set at $18.00.

Organon & Co. (NYSE:OGN - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of $0.93 per share and revenue of $1.55 billion for the quarter.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.13. The business had revenue of $1.51 billion for the quarter, compared to analyst estimates of $1.53 billion. Organon & Co. had a return on equity of 227.43% and a net margin of 11.92%. The firm's revenue was down 6.7% on a year-over-year basis. During the same period last year, the company earned $1.22 EPS. On average, analysts expect Organon & Co. to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Organon & Co. Trading Up 0.1%

OGN stock traded up $0.01 during midday trading on Friday, hitting $9.71. 2,578,616 shares of the company's stock were exchanged, compared to its average volume of 4,410,172. Organon & Co. has a one year low of $8.01 and a one year high of $23.10. The company has a debt-to-equity ratio of 16.49, a quick ratio of 1.15 and a current ratio of 1.67. The company has a market cap of $2.52 billion, a PE ratio of 3.38, a price-to-earnings-growth ratio of 1.04 and a beta of 0.60. The stock's fifty day moving average price is $9.75 and its 200-day moving average price is $12.18.

Wall Street Analyst Weigh In

OGN has been the topic of a number of research reports. Evercore ISI lowered Organon & Co. from an "outperform" rating to an "inline" rating in a report on Friday, May 2nd. Piper Sandler dropped their target price on Organon & Co. from $24.00 to $18.00 and set an "overweight" rating on the stock in a report on Thursday, May 15th. BNP Paribas upgraded Organon & Co. to a "strong-buy" rating in a report on Thursday, May 22nd. Finally, Morgan Stanley dropped their target price on Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $18.00.

Insider Transactions at Organon & Co.

In other news, CEO Kevin Ali bought 34,000 shares of the firm's stock in a transaction dated Monday, May 5th. The shares were bought at an average price of $8.80 per share, with a total value of $299,200.00. Following the completion of the transaction, the chief executive officer owned 282,731 shares of the company's stock, valued at $2,488,032.80. This trade represents a 13.67% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Kirke Weaver bought 8,045 shares of the firm's stock in a transaction dated Tuesday, May 6th. The stock was purchased at an average cost of $9.21 per share, for a total transaction of $74,094.45. Following the transaction, the insider directly owned 52,489 shares of the company's stock, valued at $483,423.69. The trade was a 18.10% increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 102,345 shares of company stock worth $902,430 over the last three months. Company insiders own 1.96% of the company's stock.

Institutional Investors Weigh In On Organon & Co.

Large investors have recently added to or reduced their stakes in the stock. Focus Partners Wealth lifted its stake in shares of Organon & Co. by 33.2% in the 1st quarter. Focus Partners Wealth now owns 55,875 shares of the company's stock valued at $832,000 after acquiring an additional 13,925 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of Organon & Co. by 53.4% in the 1st quarter. Royal Bank of Canada now owns 360,862 shares of the company's stock valued at $5,374,000 after acquiring an additional 125,648 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Organon & Co. by 2.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,042,991 shares of the company's stock valued at $15,530,000 after acquiring an additional 26,640 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Organon & Co. by 126.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company's stock worth $21,370,000 after purchasing an additional 801,307 shares during the last quarter. Institutional investors and hedge funds own 77.43% of the company's stock.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.